|
US9937531B2
(en)
|
2009-03-10 |
2018-04-10 |
Bookit Oy Ajanvarauspalvelu |
Method and system for delivery of goods
|
|
WO2003063822A2
(en)
|
2002-02-01 |
2003-08-07 |
Pfizer Products Inc. |
Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
|
|
WO2003075836A2
(en)
|
2002-03-05 |
2003-09-18 |
Merck Frosst Canada & Co. |
Cathepsin cysteine protease inhibitors
|
|
AU2003221092A1
(en)
*
|
2002-03-19 |
2003-09-29 |
Kowa Co., Ltd. |
Preventives/remedies for myeloma tumor and method of diagnosing the same
|
|
EP1631548B1
(en)
*
|
2003-04-24 |
2009-10-28 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
|
CN1839114A
(zh)
*
|
2003-08-21 |
2006-09-27 |
默克弗罗斯特加拿大有限公司 |
组织蛋白酶半胱氨酸蛋白酶抑制剂
|
|
AU2004268707A1
(en)
*
|
2003-08-27 |
2005-03-10 |
Merck Frosst Canada Ltd |
Cathepsin inhibitors
|
|
BRPI0410979A
(pt)
*
|
2003-09-18 |
2006-07-04 |
Axys Pharm Inc |
composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
|
|
WO2005040142A1
(en)
|
2003-10-24 |
2005-05-06 |
Aventis Pharmaceuticals Inc. |
Novel keto-oxadiazole derivatives as cathepsin inhibitors
|
|
CN100548986C
(zh)
*
|
2003-12-12 |
2009-10-14 |
默克弗罗斯特加拿大有限公司 |
组织蛋白酶半胱氨酸蛋白酶抑制剂
|
|
WO2005065778A1
(en)
*
|
2004-01-08 |
2005-07-21 |
Merck Frosst Canada Ltd. |
Cathepsin cysteine protease inhibitors
|
|
US7429674B2
(en)
|
2004-04-14 |
2008-09-30 |
Merck & Co. Inc.. |
Process for preparing fluoroleucine alkyl esters
|
|
WO2006017455A2
(en)
|
2004-08-04 |
2006-02-16 |
Merck & Co., Inc. |
Diastereoselective reductive amination process
|
|
US7737300B2
(en)
*
|
2004-09-17 |
2010-06-15 |
Virobay, Inc. |
Processes and intermediates preparing cysteine protease inhibitors
|
|
TW200619206A
(en)
*
|
2004-09-29 |
2006-06-16 |
Anormed Inc |
Chemokine-binding heterocyclic compound salts, and methods of use thereof
|
|
AR055283A1
(es)
*
|
2004-11-23 |
2007-08-15 |
Merck Frosst Canada Ltd |
Inhibidores de cisteinproteasa de catepsina
|
|
WO2006060494A1
(en)
|
2004-12-01 |
2006-06-08 |
Schering Aktiengesellschaft |
Haloalkyl containing compounds as cysteine protease inhibitors
|
|
EP1819667B1
(en)
*
|
2004-12-02 |
2012-10-17 |
ViroBay, Inc. |
Sulfonamide compounds as cysteine protease inhibitors
|
|
WO2006076797A1
(en)
*
|
2005-01-19 |
2006-07-27 |
Merck Frosst Canada Ltd. |
Cathepsin k inhibitors and atherosclerosis
|
|
WO2006076796A1
(en)
*
|
2005-01-19 |
2006-07-27 |
Merck Frosst Canada Ltd. |
Cathepsin k inhibitors and obesity
|
|
WO2006093467A1
(en)
*
|
2005-03-02 |
2006-09-08 |
Agency For Science, Technology And Research |
Conjugated organic molecules for molecular electronic devices
|
|
CN104188952A
(zh)
*
|
2005-03-02 |
2014-12-10 |
默沙东公司 |
抑制组织蛋白酶k的组合物
|
|
EP1865940B1
(en)
|
2005-03-21 |
2013-02-13 |
Virobay, Inc. |
Alpha ketoamide compounds as cysteine protease inhibitors
|
|
JP5215167B2
(ja)
*
|
2005-03-22 |
2013-06-19 |
ビロベイ，インコーポレイティド |
システインプロテアーゼ阻害剤としてのスルホニル基含有化合物
|
|
US20090099264A1
(en)
|
2005-06-02 |
2009-04-16 |
Merck Frosst Canada Ltd. |
Fluoroalkylamine Derivatives as Cathepsin Inhibtors
|
|
JP5311822B2
(ja)
|
2005-07-19 |
2013-10-09 |
第一三共株式会社 |
置換プロパンアミド誘導体及びそれを含む医薬組成物
|
|
US20090264479A1
(en)
*
|
2005-07-26 |
2009-10-22 |
Cameron Black |
Papain Family Cysteine Protease Inhibitors for the Treatment of Parasitic Diseases
|
|
WO2007137738A1
(de)
*
|
2006-06-01 |
2007-12-06 |
Sanofi-Aventis |
Spiro-cyclische nitrile als protease-inhibitoren
|
|
US7622593B2
(en)
*
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7893112B2
(en)
*
|
2006-10-04 |
2011-02-22 |
Virobay, Inc. |
Di-fluoro containing compounds as cysteine protease inhibitors
|
|
CA2664878A1
(en)
*
|
2006-10-04 |
2008-04-10 |
Virobay, Inc. |
Di-fluoro containing compounds as cysteine protease inhibitors
|
|
CN101616908B
(zh)
*
|
2006-12-29 |
2014-09-10 |
Abbvie德国有限责任两合公司 |
羧酰胺化合物及它们作为钙蛋白酶抑制剂的用途
|
|
WO2008106059A1
(en)
|
2007-02-26 |
2008-09-04 |
Merck & Co., Inc. |
Formulations for cathepsin k inhibitors
|
|
WO2008119176A1
(en)
*
|
2007-04-02 |
2008-10-09 |
Merck Frosst Canada Ltd. |
Amidation process for the preparation of cathepsin k inhibitors
|
|
US20110092484A1
(en)
|
2007-06-08 |
2011-04-21 |
Nippon Chemiphar Co., Ltd. |
Therapeutic or prophylactic agent for cerebral aneurysm
|
|
EP2216047A4
(en)
|
2007-10-24 |
2011-12-28 |
Nat Univ Corp Tokyo Med & Dent |
Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient
|
|
ES2533875T3
(es)
*
|
2007-11-29 |
2015-04-15 |
Merck Canada Inc. |
Inhibidores de la cisteína proteasa para el tratamiento de enfermedades parasitarias
|
|
JPWO2009096198A1
(ja)
*
|
2008-02-01 |
2011-05-26 |
一般社団法人ファルマＩｐ |
新規ビアリール誘導体
|
|
BRPI0822420A2
(pt)
*
|
2008-04-01 |
2014-10-07 |
Virobay Inc |
Composto, composição farmaceutica, e, métodos para tratar uma doença em uma animal e para tratar um paciente que passa por uma tarepia.
|
|
WO2009125861A1
(ja)
*
|
2008-04-09 |
2009-10-15 |
帝人ファーマ株式会社 |
システインプロテアーゼ阻害剤
|
|
US20110065800A1
(en)
*
|
2008-05-14 |
2011-03-17 |
Haihong Fan |
Formulations for cathepsin k inhibitors
|
|
PL2421826T3
(pl)
|
2009-04-20 |
2014-03-31 |
Hoffmann La Roche |
Pochodne proliny jako inhibitory katepsyn
|
|
US8324417B2
(en)
*
|
2009-08-19 |
2012-12-04 |
Virobay, Inc. |
Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
|
|
US9051304B2
(en)
*
|
2009-12-22 |
2015-06-09 |
AbbVie Deutschland GmbH & Co. KG |
Carboxamide compounds and their use as calpain inhibitors V
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
EP2675440B1
(en)
*
|
2011-02-14 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
|
WO2012148555A1
(en)
*
|
2011-03-02 |
2012-11-01 |
Merck Sharp & Dohme Corp. |
Amidation process
|
|
WO2012151319A1
(en)
|
2011-05-02 |
2012-11-08 |
Virobay, Inc. |
Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain
|
|
JP6000340B2
(ja)
|
2011-05-16 |
2016-09-28 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ |
肺高血圧症および／または心不全の治療および／または予防のためのカテプシンｋ阻害の使用
|
|
BR112014016870A2
(pt)
|
2012-01-09 |
2017-06-27 |
Huesken Dieter |
composições orgânicas para tratar doenças relacionadas com beta-catenina
|
|
PE20190736A1
(es)
|
2012-06-13 |
2019-05-23 |
Incyte Holdings Corp |
Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
|
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US20140199495A1
(en)
|
2013-01-11 |
2014-07-17 |
Floor Iptech Ab |
Digital printing and embossing
|
|
DK2958907T3
(en)
|
2013-02-19 |
2018-06-06 |
Novartis Ag |
Thus, benzothiophene derivatives and compositions as selective estrogen receptor degraders
|
|
KR102194745B1
(ko)
|
2013-03-13 |
2020-12-24 |
포르마 세라퓨틱스 인크. |
Ｆａｓｎ 억제용 신규 화합물 및 조성물
|
|
KR102269032B1
(ko)
|
2013-04-19 |
2021-06-24 |
인사이트 홀딩스 코포레이션 |
Fgfr 저해제로서 이환식 헤테로사이클
|
|
US20160081937A1
(en)
|
2013-05-16 |
2016-03-24 |
Sandoz Ag |
Tablet with increased drug load of odanacatib
|
|
EP2808012A1
(en)
|
2013-05-29 |
2014-12-03 |
ratiopharm GmbH |
Method for producing dosage form comprising odanacatib
|
|
EP3009425B1
(en)
|
2013-06-14 |
2018-06-06 |
Seikagaku Corporation |
Alpha-oxoacylaminocaprolactam
|
|
WO2014199644A1
(ja)
|
2013-06-14 |
2014-12-18 |
生化学工業株式会社 |
α－オキソアシルアミノカプロラクタム誘導体
|
|
WO2015006177A1
(en)
*
|
2013-07-11 |
2015-01-15 |
Merck Sharp & Dohme Corp. |
Formulations for cathepsin k inhibitors with vitamin d
|
|
KR20160065854A
(ko)
*
|
2013-10-08 |
2016-06-09 |
머크 샤프 앤드 돔 코포레이션 |
카텝신 시스테인 프로테아제 억제제
|
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
CN105899491B
(zh)
|
2014-01-17 |
2019-04-02 |
诺华股份有限公司 |
用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物
|
|
CN105899493B
(zh)
|
2014-01-17 |
2019-03-29 |
诺华股份有限公司 |
用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CZ2014941A3
(cs)
|
2014-12-19 |
2016-06-29 |
Zentiva, K.S. |
Příprava vysoce čistého intermediátu pro syntézu Odanacatibu
|
|
ES2895769T3
(es)
|
2015-02-20 |
2022-02-22 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores de FGFR
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
RU2017134379A
(ru)
|
2015-03-25 |
2019-04-03 |
Новартис Аг |
Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4
|
|
EP3310771B1
(en)
|
2015-06-19 |
2020-07-22 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
|
CN112625028B
(zh)
|
2015-06-19 |
2024-10-29 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物
|
|
EP3310779B1
(en)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
|
EP3342765B1
(en)
*
|
2015-08-29 |
2021-09-15 |
Sunshine Lake Pharma Co., Ltd. |
Cathepsin k inhibitor and application thereof
|
|
CN108368056A
(zh)
*
|
2015-11-26 |
2018-08-03 |
豪夫迈·罗氏有限公司 |
锥虫抑制剂
|
|
CN106866502B
(zh)
*
|
2015-12-10 |
2020-10-09 |
广东东阳光药业有限公司 |
组织蛋白酶k抑制剂及其用途
|
|
US10577362B2
(en)
|
2016-05-04 |
2020-03-03 |
Genoscience Pharma |
Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
|
|
WO2017216706A1
(en)
|
2016-06-14 |
2017-12-21 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
|
SI3575284T1
(sl)
*
|
2017-01-24 |
2021-11-30 |
Astellas Pharma Inc. |
Spojina fenildifluorometil substituiranega prolinamida
|
|
KR101916396B1
(ko)
|
2017-02-20 |
2018-11-08 |
서울대학교 산학협력단 |
항암제 또는 항균제로 사용될 수 있는 단백질분해효소 저해제
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
TWI851542B
(zh)
|
2017-09-11 |
2024-08-11 |
美商克魯松藥物公司 |
Ｓｈｐ２之八氫環戊烷并[c]吡咯別構抑制劑
|
|
NL2020021B1
(en)
*
|
2017-12-05 |
2019-06-13 |
Academisch Ziekenhuis Leiden |
Cathepsin inhibitors
|
|
ES2908999T3
(es)
|
2017-12-05 |
2022-05-04 |
Academisch Ziekenhuis Leiden |
Inhibidores de catepsina
|
|
KR102709682B1
(ko)
|
2018-03-28 |
2024-09-25 |
한림제약(주) |
2-시아노피리미딘-4-일 카르바메이트 혹은 유레아 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
|
|
SG11202010882XA
(en)
|
2018-05-04 |
2020-11-27 |
Incyte Corp |
Salts of an fgfr inhibitor
|
|
SI3788047T1
(sl)
|
2018-05-04 |
2024-11-29 |
Incyte Corporation |
Trdne oblike inhibitorja fgfr in postopki priprave le-teh
|
|
AU2019344897B2
(en)
|
2018-09-18 |
2024-01-18 |
Nikang Therapeutics, Inc. |
Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors
|
|
CN113382986A
(zh)
|
2018-09-25 |
2021-09-10 |
黑钻治疗公司 |
酪氨酸激酶抑制剂组合物、其制备方法和使用方法
|
|
JP2022502496A
(ja)
|
2018-09-25 |
2022-01-11 |
ブラック ダイアモンド セラピューティクス，インコーポレイティド |
チロシンキナーゼ阻害剤組成物、作製方法、および使用方法
|
|
CA3113379A1
(en)
|
2018-09-29 |
2020-04-02 |
Novartis Ag |
Process of manufacture of a compound for inhibiting the activity of shp2
|
|
TWI767148B
(zh)
|
2018-10-10 |
2022-06-11 |
美商弗瑪治療公司 |
抑制脂肪酸合成酶(fasn)
|
|
EP3873214A4
(en)
|
2018-10-29 |
2022-07-13 |
Forma Therapeutics, Inc. |
Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2020201572A1
(en)
|
2019-04-05 |
2020-10-08 |
Université De Bretagne Occidentale |
Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CN114787150A
(zh)
|
2019-08-15 |
2022-07-22 |
黑钻治疗公司 |
炔基喹唑啉化合物
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11607416B2
(en)
|
2019-10-14 |
2023-03-21 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2021113462A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
CN114539111A
(zh)
*
|
2020-11-19 |
2022-05-27 |
深圳信立泰药业股份有限公司 |
奥当卡替的盐及其制备方法和医药用途
|
|
WO2022140472A1
(en)
|
2020-12-22 |
2022-06-30 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
|
WO2022152821A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
EP4323349A1
(en)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinone amide compounds useful to treat diseases associated with gspt1
|
|
EP4323350A1
(en)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinone compounds
|
|
WO2022261160A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2023284730A1
(en)
|
2021-07-14 |
2023-01-19 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
|
US12331026B2
(en)
|
2022-03-28 |
2025-06-17 |
Nikang Therapeutics, Inc. |
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
|
|
WO2023240024A1
(en)
|
2022-06-08 |
2023-12-14 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
AU2023375457A1
(en)
|
2022-11-11 |
2025-05-01 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|
|
WO2025072462A1
(en)
|
2023-09-27 |
2025-04-03 |
Nikang Therapeutics, Inc. |
Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
TW202527955A
(zh)
|
2023-11-27 |
2025-07-16 |
美商尼坎醫療公司 |
用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶２和週期蛋白依賴性激酶４的含有２，５－取代的嘧啶衍生物的雙功能化合物
|
|
WO2025117981A1
(en)
|
2023-12-02 |
2025-06-05 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|
|
WO2025212828A1
(en)
|
2024-04-03 |
2025-10-09 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
WO2025240536A1
(en)
|
2024-05-15 |
2025-11-20 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|